HGH Fragment 176-191：未修饰的生长激素脂解片段

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is HGH Fragment 176-191?

HGH Fragment 176-191 (also written as hGH Frag 176-191 or HGH Frag) is a synthetic peptide corresponding to the C-terminal region of human growth hormone. Specifically, it consists of amino acids 176 through 191 of the full 191-amino-acid hGH sequence. This 16-amino-acid fragment represents the portion of the growth hormone molecule that researchers at Monash University identified as containing the molecular determinants of GH's lipolytic (fat-metabolizing) activity.

The fragment is the unmodified native sequence, distinguishing it from AOD-9604, which is the same fragment with an additional tyrosine residue at the N-terminus. Both compounds derive from the same research lineage and share the same fundamental biological premise: that the fat-metabolizing properties of growth hormone can be isolated from its other systemic effects by using only the relevant molecular fragment.

Mechanism of Action

The proposed mechanism of HGH Fragment 176-191 parallels that described for AOD-9604, as both peptides derive from the same active region of growth hormone. Based on preclinical research, the fragment is thought to act through the following pathways:

• Stimulation of lipolysis: The fragment appears to activate lipolytic pathways in adipose tissue, promoting the breakdown of stored triglycerides into free fatty acids and glycerol. Research suggests this may involve interaction with beta-adrenergic receptor-mediated signaling in fat cells.
• Inhibition of lipogenesis: In addition to promoting fat breakdown, the fragment has been shown in preclinical studies to reduce de novo fatty acid synthesis, potentially reducing the rate at which new fat is stored.
• Selective fat metabolism: Unlike full-length growth hormone, HGH Fragment 176-191 is reported to not stimulate the GH receptor in the manner necessary to activate JAK2-STAT5 signaling and IGF-1 production. This selectivity is the key theoretical advantage of the fragment approach.
• No glucose perturbation: Preclinical data suggest the fragment does not alter blood glucose or insulin sensitivity, avoiding the diabetogenic potential associated with supraphysiological GH administration.

Research Landscape

The research base for HGH Fragment 176-191 is primarily preclinical, with the majority of formal clinical development having been conducted with the modified AOD-9604 variant. Key preclinical findings include:

• Studies in obese mouse models (ob/ob mice) demonstrated that administration of the hGH 177-191 fragment (note: the research literature sometimes references the 177-191 region, which includes the same active domain) reduced body fat without affecting overall growth, food intake, or IGF-1 levels.
• In vitro studies using human adipocyte cultures showed that the fragment stimulated lipolysis in a dose-dependent manner, supporting the fat-metabolizing hypothesis.
• Comparative studies suggested that the fragment's lipolytic potency was comparable to or slightly lower than that of the full-length growth hormone molecule, but without the growth-promoting or glucose-altering effects.

The decision by Metabolic Pharmaceuticals to advance the modified AOD-9604 rather than the unmodified fragment into clinical development was based on data suggesting slightly improved stability and bioactivity with the tyrosine addition. As a result, the unmodified fragment has less human clinical data available.

Key Studies

The foundational research for both HGH Fragment 176-191 and AOD-9604 was published by researchers at Monash University in the late 1990s and early 2000s. These studies established that the C-terminal domain of growth hormone contained a lipolytic region distinct from the somatotropic (growth-promoting) region located in the N-terminal domain. The key insight was that growth hormone's various biological activities could be structurally separated, opening the door to fragment-based therapeutic approaches.

Safety Profile

Direct clinical safety data for the unmodified HGH Fragment 176-191 is limited. However, based on the available preclinical data and the clinical safety data from its closely related modified form AOD-9604, the following safety profile can be cautiously inferred:

The absence of comprehensive clinical safety data for the unmodified fragment specifically means that safety conclusions should be drawn with appropriate caution. The GRAS designation obtained by AOD-9604 applies to that specific compound and formulation, not to HGH Fragment 176-191.

Comparison to Related Compounds

HGH Fragment 176-191 exists within a spectrum of growth hormone-related peptides used in research. Compared to full-length growth hormone, it offers theoretical selectivity for fat metabolism without systemic GH effects. Compared to AOD-9604, it lacks the stabilizing N-terminal tyrosine modification and has a thinner evidence base. Compared to modern GLP-1 receptor agonists for metabolic health, its evidence for clinically meaningful fat loss is substantially weaker.

Current Status

HGH Fragment 176-191 is not approved for therapeutic use by any regulatory authority. It is available through research peptide suppliers and is commonly encountered in the peptide research community. The compound's appeal lies in its theoretical mechanism of selective lipolysis without GH side effects. However, the lack of robust clinical efficacy data, combined with the advancement of far more potent metabolic therapeutics (GLP-1 agonists, dual and triple agonists), means that HGH Fragment 176-191 occupies a niche position in the research landscape. Individuals interested in this compound should be aware of its limited evidence base and investigational status.